A5030069199- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Sclerosis and Related Diseases
- Autoimmune and Inflammatory Disorders Research
- Osteoarthritis Treatment and Mechanisms
- Systemic Lupus Erythematosus Research
- Gout, Hyperuricemia, Uric Acid
- Psoriasis: Treatment and Pathogenesis
- Inflammatory Myopathies and Dermatomyositis
- Dermatologic Treatments and Research
- Inflammatory Bowel Disease
- Chronic Lymphocytic Leukemia Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Total Knee Arthroplasty Outcomes
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Arrhythmias and Treatments
- Respiratory Support and Mechanisms
- Housing Market and Economics
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Biosimilars and Bioanalytical Methods
- Viral Infections and Vectors
- Vasculitis and related conditions
- Musculoskeletal Disorders and Rehabilitation
- Urban, Neighborhood, and Segregation Studies
Waikato Hospital
2016-2025
University of Auckland
2015-2024
Waikato District Health Board
2014-2024
American College of Rheumatology
2020-2024
Nephrologisches Zentrum Goettingen
2022-2023
RELX Group (United States)
2022-2023
Hamilton Health Sciences
2022-2023
Footscray Hospital
2022-2023
Dialyse Centrum Groningen
2022-2023
Cooperative Trials Group for Neuro-Oncology
2022-2023
Objective To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD). Methods In the randomised, placebo-controlled, double-blind KEEPsAKE 1 trial, 964 PsA were randomised (1:1) receive risankizumab 150 mg placebo at weeks 0, 4 and 16. The primary endpoint was proportion of achieving ≥20% improvement...
Objective To examine the performance of ultrasound (US) for diagnosis gout using presence monosodium urate monohydrate (MSU) crystals as gold standard. Methods We analyzed data from Study Updated Gout Classification Criteria (SUGAR), a large, multicenter observational cross‐sectional study consecutive subjects with at least 1 swollen joint who conceivably may have gout. All underwent arthrocentesis; cases were confirmed MSU crystals. Rheumatologists or radiologists blinded regard to results...
To establish consensus for potential remission criteria to use in clinical trials of gout.Experts (n = 88) gout from multiple countries were invited participate a web-based questionnaire study. Three rounds Delphi exercises conducted using SurveyMonkey, followed by discrete-choice experiment 1000Minds software. The focused on identifying domains, definitions each domain, and the timeframe over which should be defined.There 49 respondents (56% response) initial survey, with subsequent...
Abstract Objective PsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options long-term efficacy and safety. In this follow-up analysis, the 52-week safety of risankizumab 150 mg in patients active who had previous inadequate response/intolerance to one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated. Methods KEEPsAKE 1 an ongoing, global, phase 3 study 24-week, double-blind, placebo-controlled period (period 1) open-label extension 2)....
This study aims to provide updated data on the incidence and prevalence of systemic lupus erythematosus (SLE) in New Zealand examine difference between ethnic groups.We identified SLE cases from national administrative datasets. The date first identification was earliest a related inpatient event or outpatient event. crude 2010-2021 were estimated by gender, age group ethnicity. WHO (World Health Organization) age-standardised rate (ASR) calculated, after stratifying ethnicity gender.The...
Benzbromarone is a potent uricosuric but not widely available due to concerns about hepatotoxicity. In Aotearoa New Zealand, benzbromarone has been since April 2013, subject funding restrictions, for patients with inadequate urate-lowering response or intolerance allopurinol and probenecid.To assess the safety efficacy of in real-life setting.All who received from 1 2013 30 September 2014 were identified. Prescribers sent questionnaire each individual. Information on demographics, previous...
Abstract Background/Aims The presence of both small and large bowel inflammation in patients with axial spondyloarthritis (axSpA) is well documented. Numerous studies employing ileocolonoscopy suggest a prevalence 40-65%. Gut lesions also correspond non-invasive markers, including elevated CRP faecal calprotectin, but symptomatic Inflammatory disease present only ∼ 8% axSpA, the remainder said to have silent, asymptomatic or subclinical inflammation. We considered that this gut was unlikely...
Abstract Introduction HLA-B27 genotyping is commonly used to support a diagnosis of ankylosing spondylitis (AS). A recent study has suggested that may adversely affect longevity. The objectives this were determine, for the first time, prevalence in New Zealand population, and test whether declines with age. Methods 117 Caucasian controls, 111 Māori 176 AS patients directly genotyped using PCR-SSP. These participants further 1103 controls tagging single nucleotide polymorphisms (SNPs)...
Coronary and systemic hemodynamics were compared in 15 normal men women. Systemic very similar. The women had 26.5 per cent greater coronary flow 19.6 more oxygen consumption/100 Gm. of left ventricular myocardium. Their calculated vascular resistance was 35 less. Significant negative correlations between heart weight, cardiac consumption as well hematocrit probably explain the differences part. Whether hormonal or anatomic are also significant is not known.
Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well safety. We present 100-week and safety results of risankizumab patients active PsA previous inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR). KEEPsAKE (NCT03675308) is a global phase 3 study, including 24-week, double-blind, placebo-controlled ongoing open-label extension periods. were randomized 1:1...
PULMONARY hypertension is a common complication of diffuse obstructive pul- monary emphysema.'While obliteration the pulmonary vascular bed may be prin- cipal factor that causes hypertension, it apparent other factors, sueh as hypoxia, increased cardiac output, and vasomotor tone, are important contributing elements.2In most instances in which there resting hyperten- sion, an increase such produced by exercise, accompanied artery pressure constant or rising resist- ance.3It purpose present...
This study aims to assess the mortality of systemic lupus erythematosus (SLE) patients and examine whether there are variations by subgroup.
Abstract This study aims to examine the prevalence and outcomes of end-stage kidney disease (ESKD) among systemic lupus erythematosus (SLE) patients. SLE patients identified from national administrative datasets were linked Australia New Zealand Dialysis Transplant Registry (ANZDATA) identify ESKD cases. Period was calculated. The risk developing by ethnicity explored with Cox Proportional Hazards model. adjusted hazard ratio (HR) all-cause mortality for Māori, Pacific, Asian compared...